Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer

Tumori

Volumn 84, Issue 6, 1998, Pages 669-672

  Clerici, M ^a   De Marinis, F ^a   Piazza, E ^a   Frontini, L ^a   Tucci, E ^a   Barni, S ^a   Bretti, S ^a   Luporini, G ^a   Intini, C ^a  

^a S Giuseppe Hospital   (Italy)

Author keywords

Chemotherapy; Cisplatin; Epirubicin; High dose chemotherapy; NSCLC

Indexed keywords

CISPLATIN; EPIRUBICIN;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; VOMITING;

EID: 0032460548     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400611     Document Type: Article

References (21)